Day: January 13, 2023

Posted on

The stage is set for the inaugural ICC U19 Women’s T20 World Cup 

Dubai, January 13, 2023 (PPI-OT):The stage is set for the inaugural ICC U19 Women’s T20 World Cup 2023. The 16 captains assembled for their historical photo at Nelson Mandela Square in Johannesburg.

The captains’ gathering marks the start of the tournament, featuring a breakfast event with tournament ambassador, Mithali Raj. The 16 future stars were given the opportunity to engage with her about her vast World Cup experience and received insight on how to tackle game day nerves, bouncing back from losses, leadership styles and how to grow and maintain a strong brand.

The first of the 41 matches get started at Willow Moore Park Stadium in Benoni, with the tournament running from 14-29 January when the first-ever champions will be crowned.

Groups A and D get the tournament underway when Australia take on Bangladesh and the United Arab Emirates (UAE) go head-to-head against Scotland at 10h00 Willow Moore Park and Willow Moore Park B Field in Benoni.

They are followed by hosts, South Africa, who go up against India and Sri Lanka who face off the United States of America (USA) at the same venues.

South Africa captain, Oluhle Siyo said: “It feels like today has taken so long to get to, but we’re finally here. The World Cup has officially begun. It was so awesome to meet all of the captains during the captains’ photo, this tournament is going to be so much fun. As a team, we’re really excited to be hosts and to also play in our first-ever World Cup. We’ve worked hard to prepare for this moment and we just want to get started and show what we’re made of.”

Australia Captain, Rhys McKenna said: “It was pretty cool being able to meet all the other captains and being able to see the trophy up close made me pretty itchy to get the win. It’s been a pretty hectic few days since we’ve gotten to South Africa, we’ve either been training or playing (warm-up) games or doing lots of talks but it’s been pretty good to get a look at the other teams. We’re excited for Saturday, definitely.

India captain, Shafali Verma said: “Our first week of the U19 T20 World Cup has been really exciting and busy. We’ve done everything from training to warm-up games, to workshops about health and wellness, media and integrity.

You can’t help but feel like you’re part of something new and historic. Today’s captains’ photo was definitely one of my standout moments of the build-up so far. It was such a festive atmosphere. We’re excited for our first match on Saturday.

UAE captain Theertha Satish said: “Our first week in South Africa has been so amazing. We’ve been to so many new grounds, we’ve met so many new people. The experience has just been amazing and we’ve enjoyed it to the fullest.

We got a good opportunity to meet big stars who have been there and done that and have shared very valuable information with us on how they have gone about their own World Cup experiences, we’re excited to put those lessons to action. Taking the photo with the other captains and getting to meet them and make new friends was probably one of my best highlights so far. We can’t wait for Saturday to finally arrive.

For more information, contact:
Headquarters,
International Cricket Council (ICC)
Street 69, Dubai Sports City,
Sh Mohammed Bin Zayed Road, Dubai, UAE
Phone: +97-143828800
Fax: +97-143828600
E-mail: enquiry@icc-cricket.com
Website: www.icc-cricket.com

Posted on

McColl approved as replacement for Barbour-Smith in Scotland squad 

Dubai, January 13, 2023 (PPI-OT):The Event Technical Committee of the ICC U19 Women’s T20 World Cup 2023 has approved Kirsty McColl as a replacement for Molly Barbour-Smith in the Scotland Squad. McColl was named as a replacement after Barbour-Smith was ruled out after sustaining a fractured finger.

The replacement of a player requires the approval of the Event Technical Committee before the replacement player can be officially added to the squad.

The Event Technical committee of the ICC U19 Women’s T20 World Cup 2023 consists of Sarah Edgar (Chair), ICC Senior Manager Event Operations, Snehal Pradhan, ICC Women’s Cricket Manager, Sivuyile Mqingwana, Tournament Director, Claire Terblanche, (Cricket South Africa), Lydia Greenway (Independent), Stacy-Ann King (Independent).

For more information, contact:
Headquarters,
International Cricket Council (ICC)
Street 69, Dubai Sports City,
Sh Mohammed Bin Zayed Road, Dubai, UAE
Phone: +97-143828800
Fax: +97-143828600
E-mail: enquiry@icc-cricket.com
Website: www.icc-cricket.com

Posted on

1 in 2 Pakistanis say that they have at least some level of confidence in property dealers: Gallup and Gilani Pakistan 

Islamabad, January 13, 2023 (PPI-OT):According to a survey conducted by Gallup and Gilani Pakistan, 1 in 2 Pakistanis say that they have at least some level of confidence in property dealers.

A nationally representative sample of adult men and women from across the country was asked the following question regarding, “Please indicate how confident you are in the following: In Property Dealers?” 12% said they’re completely confident, 21% said they are somewhat confident, 17% reported slight confidence while 31% said they are not at all confident in property dealers whereas 19% did not respond or said that they did not know.

Question: “Please indicate how confident you are in the following: In Property Dealers”

For more information, contact:
Head Office,
Gallup Pakistan
Islamabad, Pakistan
Tel: +92-51-8445080
Email: isb@gallup.com.pk, caf@gallup.com.pk
Website: www.gallup.com.pk

Posted on

ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages Avaya Holdings Corp. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action – AVYA, AVYAW

NEW YORK, Jan. 12, 2023 (GLOBE NEWSWIRE) — WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Avaya Holdings Corp. (NYSE: AVYA) (OTC: AVYAW) between November 22, 2021 and November 29, 2022, both dates inclusive (the “Class Period”). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than March 6, 2023.

SO WHAT: If you purchased Avaya securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the Avaya class action, go to https://rosenlegal.com/submit-form/?case_id=8033 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than March 6, 2023. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources or any meaningful peer recognition. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs’ Bar. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the lawsuit, throughout the Class Period, defendants made false and/or misleading statements and/or failed to disclose that: (1) the Company’s internal control over financial reporting (“ICFR”) was deficient in several areas; (2) as a result of these deficiencies, the Company had failed to design and maintain effective controls over its whistleblower policies and its ethics and compliance program; (3) the Company’s deteriorating financial condition was likely to raise substantial doubt as to its ability to continue as a going concern; and (4) as a result, the Company’s public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the Avaya class action, go to https://rosenlegal.com/submit-form/?case_id=8033 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Contact Information:

        Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827
lrosen@rosenlegal.com
pkim@rosenlegal.com
cases@rosenlegal.com
www.rosenlegal.com

GlobeNewswire Distribution ID 8729172

Posted on

Sabin Vaccine Institute Receives $35 Million from BARDA with Potential of up to $214 Million for Ebola Sudan and Marburg Vaccines

Sabin Vaccine Institute Awarded BARDA Contract With Funding Potential up to $214M for Ebola Sudan and Marburg Vaccines

The Sabin Vaccine Institute will produce up to 100,000 doses of Sabin’s Ebola Sudan vaccine as part of a new, multi-year contract with BARDA

WASHINGTON, Jan. 12, 2023 (GLOBE NEWSWIRE) — The Sabin Vaccine Institute today announced that the Biomedical Advanced Research and Development Authority (BARDA) has awarded Sabin a multi-year contract with funding potential for up to $214 million to advance the development and production of single-dose vaccine candidates for Ebola Sudan and Marburg virus diseases.

There are currently no licensed vaccines against Ebola Sudan and Marburg viruses, which cause hemorrhagic fever and kill approximately half the people infected.

BARDA, part of the U.S. Department of Health and Human Services’ Administration for Strategic Preparedness and Response (ASPR), will initially invest approximately $35 million to produce up to 100,000 doses of Sabin’s Ebola Sudan virus (ChAd3-SUDV) vaccine. These vaccines may be used as part of ongoing U.S. preparedness efforts and in response to future global outbreaks.

The Sabin vaccine was the first to arrive in Uganda during the recent Ebola Sudan virus outbreak that caused 55 deaths after the World Health Organization included it as one of three vaccines for possible use in an outbreak trial in Uganda. The country declared the Ebola Sudan outbreak had ended on January 11, four months after the first confirmed case.

“Sabin successfully delivered Ebola Sudan vaccine doses to Uganda within 79 days of the start of the outbreak – quite an impressive accomplishment,” says Sabin Chief Executive Officer Amy Finan. “This new contract enables Sabin to produce up to 100,000 doses so the world is prepared in advance for future outbreaks.”

In addition to participating in recent outbreak activities, Sabin continues its Sudan development plan and has initiated Phase 2 clinical trial planning in Uganda and Kenya. Based on previous clinical trials, Sabin’s Ebola Sudan vaccine is safe and immunogenic, and in nonhuman primate studies has demonstrated rapid protection, durability up to 12 months, and efficacy.

In addition to Sabin’s ChAd3-SUDV vaccine, the contract also includes support to manufacture Sabin’s vaccine against Marburg virus (ChAd3-MARV), which would generate doses that could also be used in trials and in response to a possible Marburg virus outbreak. As recently as last July, two people in Ghana died after being infected with Marburg virus, reinforcing the urgent need for a vaccine.

The new contract leverages a partnership with BARDA that began in 2019, when the agency awarded Sabin another multi-year contract valued at $128 million to further the development of vaccines against both the Marburg and Ebola Sudan viruses.

“BARDA has been a supportive partner as we take these essential steps in pandemic preparedness,” said Finan. “The Ebola Sudan outbreak in Uganda underscored the critical need for readily available solutions. We’ll now have ample material to respond quickly to such an outbreak in the future.”

This project will be funded in whole with federal funds from the Department of Health and Human Services; Administration for Strategic Preparedness and Response; Biomedical Advanced Research and Development Authority, under contract number 75A50123C00010.

About the Sabin Vaccine Institute

The Sabin Vaccine Institute is a leading advocate for expanding vaccine access and uptake globally, advancing vaccine research and development, and amplifying vaccine knowledge and innovation. Unlocking the potential of vaccines through partnership, Sabin has built a robust ecosystem of funders, innovators, implementers, practitioners, policy makers and public stakeholders to advance its vision of a future free from preventable diseases. As a non-profit with three decades of experience, Sabin is committed to finding solutions that last and extending the full benefits of vaccines to all people, regardless of who they are or where they live. At Sabin, we believe in the power of vaccines to change the world. For more information, visit www.sabin.org and follow us on Twitter, @SabinVaccine.

About Ebola Sudan and Marburg

Ebola Sudan and Marburg are members of the filovirus family. Both can cause severe hemorrhagic fever in humans and nonhuman primates. No therapeutic treatment of these hemorrhagic fevers has been licensed to date. Marburg and Ebola viruses are transmitted to humans by infected animals, particularly fruit bats. Once a human is infected, the virus can spread to others through close personal contact or contact with bodily fluids. Isolation of infected people is currently the centerpiece of filovirus control.

Marburg was the first filovirus to be recognized in 1967 when outbreaks of hemorrhagic fever were reported in a few Europe-based laboratories including in the town of Marburg, Germany. Ebola was identified in 1976 when two simultaneous outbreaks occurred in northern Zaire (now the DRC) in a village near the Ebola River and in southern Sudan. The outbreaks involved what eventually proved to be two different species of Ebola virus; both were named after the nations in which they were discovered.

For media inquiries:

press@sabin.org

Media Contact:
Monika Guttman
Media Relations Specialist
Sabin Vaccine Institute
+1 (202) 662-1841
press@sabin.org

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/539c9127-e5d6-4b32-9e89-780f7461314b

GlobeNewswire Distribution ID 8728283